Barclays Announces Up to £500M Share Buyback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy BCS?
Q126 Group RoTE of 13.5% with EPS of 14.1p; Announced intention to initiate a share buyback of up to GBP 500M following the completion of the ongoing GBP 1B share buyback announced at FY25 Results; Q126 Group net interest income excluding Barclays Investment Bank and Head office of GBP 3.4bn, of which Barclays UK was GBP 2B, on track to meet the 2026 guidance of greater than GBP 13.5B and GBP 8.1-GBP 8.3B respectively; 5% growth in UK lending year-on-year in Q126; Delivered GBP 22B of c.GBP 30B planned UK risk weighted assets growth since 2024, of which GBP 15B was organic growth; Q126 Group cost: income ratio improving to 56% driven by positive operating leverage; Delivered c.GBP 150M of gross cost efficiency savings in Q126; Q126 Group loan loss rate of 74bps included a GBP 0.2B single name impairment charge in the IB which had a c.20bps impact on Group LLR; As a result, Group LLR in FY26 is expected to be around the top of the 50-60bps through the cycle guidance range; Strong balance sheet with CET1 ratio of 14.1%; Taking into account the impact of the GBP 500M share buyback, the CET1 ratio as of 31 March 2026 would be reduced to 13.9%, at the top end of the 13-14% range. C. Venkatakrishnan, Group Chief Executive, commented, "Barclays delivered another solid quarter with a 13.5% RoTE in Q126, and double-digit returns in all our businesses. This was despite a one-off charge and impairments in the quarter. Top line income grew 6% year-on-year, driven by broad based divisional performance including in the Investment Bank, where we generated over GBP 4bn quarterly income for the first time. The cost: income ratio improved to 56% and earnings per share grew by 8% to 14.1p. Our capital position remains robust with a 14.1% common equity tier 1 ratio and we are announcing a GBP 500M buyback today. The breadth and quality of our businesses mean we remain confident in delivering all our financial targets across a range of environments. This includes greater than 12% RoTE in 2026 and greater than 14% RoTE in 2028."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCS
About BCS
Barclays PLC is a diversified bank with five divisions comprising Barclays UK, Barclays UK Corporate Bank, Barclays Private Bank and Wealth Management, Barclays Investment Bank and Barclays US Consumer Bank. The Barclays UK division represents businesses that sit within the United Kingdom ring-fenced bank, Barclays Bank UK PLC and its subsidiaries, and comprises Personal Banking, UK Business Banking and Barclaycard Consumer UK. The Barclays UK Corporate Bank division offers lending, trade and working capital, liquidity, payments, and FX solutions for corporate clients. Barclays Private Bank and Wealth Management division comprises the Private Bank, Wealth Management, and Investments businesses. Barclays Investment Bank division incorporates the Global Markets, Investment Banking, and International Corporate Banking businesses. Barclays US Consumer Bank division represents the United States credit card business, focused on the partnership market, as well as an online deposit franchise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Barclays Abandons Fed Rate Cut Forecast
- Rate Forecast Revision: Barclays has abandoned its 2023 Fed rate cut forecast, now expecting the central bank to hold rates steady until 2026, with a potential 25-basis-point cut in March 2027, reflecting concerns over inflation progress.
- Oil Price Impact: Barclays' energy strategist projects Brent crude to peak at $115 per barrel this quarter before gradually declining to $100, while WTI is expected to peak at $105 in Q2, averaging $93 in 2026, indicating persistent inflationary pressures from high oil prices.
- Inflation Expectations Raised: Barclays has raised its 2026 Q4 PCE inflation forecast to 3.8%, 0.7 percentage points higher than previously estimated, with core PCE inflation also adjusted to 3.1%, highlighting ongoing inflationary pressures.
- GDP Growth Downgrade: Barclays has cut its 2026 GDP growth forecast by 0.3 percentage points to 2.1%, yet the resilient labor market suggests the Fed lacks justification for rate cuts in the near term.
See More
Rosen Law Firm Investigates Barclays Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Barclays PLC (NYSE: BCS) due to allegations of misleading business information, which could significantly impact numerous investors' rights.
- Potential Compensation Opportunity: Investors who purchased Barclays securities may be entitled to compensation through a contingency fee arrangement, providing crucial legal support without upfront costs.
- Market Reaction: Barclays' American Depositary Shares fell 3.99% on February 27, 2026, and 2.3% on March 2, 2026, due to its £600 million ($809.7 million) exposure to Market Financial Solutions Ltd (MFS), indicating market concerns about its financial health.
- Law Firm's Advantage: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in securities litigation.
See More
Pentair Q1 2026 Earnings Beat Expectations Amid Analyst Downgrades
- Strong Earnings Report: Pentair reported Q1 2026 revenue of $1.04 billion and adjusted EPS of $1.22, surpassing analyst expectations of $1.03 billion and $1.17, indicating robust performance in the water solutions sector.
- Stock Price Decline: Despite the strong earnings, Pentair's stock has fallen 12% since last Friday's close, reflecting market concerns over analysts' downward revisions of price targets, with Barclays, TD Cowen, and Bank of America all lowering their targets.
- Analyst Sentiment Shift: Barclays cut its price target from $95 to $92, TD Cowen from $90 to $75, and Bank of America from $88 to $80, contributing to increased selling pressure among investors.
- Management's Optimistic Outlook: Despite the bearish analyst sentiment, management forecasts 2026 EPS from continuing operations to be between $4.83 and $4.93, representing a year-over-year increase of 23% to 25%, indicating confidence in the company's growth potential.
See More
Rosen Law Firm Investigates Barclays Securities Fraud Claims
- Securities Fraud Investigation: Rosen Law Firm is investigating potential securities claims against Barclays PLC for allegedly issuing materially misleading business information, with a reported exposure of £600 million (approximately $809.7 million), which could lead to significant investor losses.
- Class Action Preparation: Investors who purchased Barclays securities during this period may be entitled to compensation through a contingency fee arrangement without any upfront costs, as Rosen Law Firm prepares a class action to recover investor losses.
- Stock Price Volatility: Barclays American Depositary Shares fell by 3.99% on February 27, 2026, and 2.3% on March 2, 2026, due to market concerns regarding its £600 million exposure to Market Financial Solutions Ltd (MFS), indicating investor apprehension about the bank's financial stability.
- Law Firm Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Barclays Abandons Fed Rate Cut Forecast
- Rate Forecast Revision: Barclays has abandoned its 2023 Fed rate cut forecast, now expecting the central bank to hold rates steady until 2026, with a potential 25-basis-point cut in March 2027, reflecting concerns over inflation progress.
- Oil Price Impact: Barclays' energy strategist projects Brent crude to peak at $115 per barrel this quarter before gradually declining to $100, while WTI is expected to peak at $105 in Q2, averaging $93 in 2026, indicating persistent inflationary pressures from high oil prices.
- Inflation Expectations Raised: Barclays has raised its 2026 Q4 PCE inflation forecast to 3.8%, 0.7 percentage points higher than previously estimated, with core PCE inflation also adjusted to 3.1%, highlighting ongoing inflationary pressures.
- GDP Growth Downgrade: Barclays has cut its 2026 GDP growth forecast by 0.3 percentage points to 2.1%, yet the resilient labor market suggests the Fed lacks justification for rate cuts in the near term.
See More
Rosen Law Firm Investigates Barclays Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Barclays PLC (NYSE: BCS) due to allegations of misleading business information, which could significantly impact numerous investors' rights.
- Potential Compensation Opportunity: Investors who purchased Barclays securities may be entitled to compensation through a contingency fee arrangement, providing crucial legal support without upfront costs.
- Market Reaction: Barclays' American Depositary Shares fell 3.99% on February 27, 2026, and 2.3% on March 2, 2026, due to its £600 million ($809.7 million) exposure to Market Financial Solutions Ltd (MFS), indicating market concerns about its financial health.
- Law Firm's Advantage: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in securities litigation.
See More
Pentair Q1 2026 Earnings Beat Expectations Amid Analyst Downgrades
- Strong Earnings Report: Pentair reported Q1 2026 revenue of $1.04 billion and adjusted EPS of $1.22, surpassing analyst expectations of $1.03 billion and $1.17, indicating robust performance in the water solutions sector.
- Stock Price Decline: Despite the strong earnings, Pentair's stock has fallen 12% since last Friday's close, reflecting market concerns over analysts' downward revisions of price targets, with Barclays, TD Cowen, and Bank of America all lowering their targets.
- Analyst Sentiment Shift: Barclays cut its price target from $95 to $92, TD Cowen from $90 to $75, and Bank of America from $88 to $80, contributing to increased selling pressure among investors.
- Management's Optimistic Outlook: Despite the bearish analyst sentiment, management forecasts 2026 EPS from continuing operations to be between $4.83 and $4.93, representing a year-over-year increase of 23% to 25%, indicating confidence in the company's growth potential.
See More
Rosen Law Firm Investigates Barclays Securities Fraud Claims
- Securities Fraud Investigation: Rosen Law Firm is investigating potential securities claims against Barclays PLC for allegedly issuing materially misleading business information, with a reported exposure of £600 million (approximately $809.7 million), which could lead to significant investor losses.
- Class Action Preparation: Investors who purchased Barclays securities during this period may be entitled to compensation through a contingency fee arrangement without any upfront costs, as Rosen Law Firm prepares a class action to recover investor losses.
- Stock Price Volatility: Barclays American Depositary Shares fell by 3.99% on February 27, 2026, and 2.3% on March 2, 2026, due to market concerns regarding its £600 million exposure to Market Financial Solutions Ltd (MFS), indicating investor apprehension about the bank's financial stability.
- Law Firm Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
